Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 66967-66970 [2016-23521]
Download as PDF
Federal Register / Vol. 81, No. 189 / Thursday, September 29, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Agency Information Collection
Activities; Proposed Collection;
Comment Request; University Centers
for Excellence in Developmental
Disabilities Education, Research, and
Service—Annual Report
The Administration on
Intellectual and Developmental
Disabilities (AIDD), Administration for
Community Living (ACL), HHS.
ACTION: Notice.
AGENCY:
The Administration on
Intellectual and Developmental
Disabilities (AIDD), now part of the
Administration for Community Living,
is announcing that the proposed
collection of information listed below
has been submitted to the Office of
Management and Budget (OMB) for
review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Submit written comments on the
collection of information by October 31,
2016.
ADDRESSES: OIRA_submission@
omb.eop.gov or by fax to 202.395.5806.
Attn: OMB Desk Officer for ACL, Office
of Information and Regulatory Affairs,
OMB.
SUMMARY:
mstockstill on DSK3G9T082PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Ophelia McLain at 202–795–7401
orophelia.mclain@acl.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, the
Administration on Intellectual and
Developmental Disabilities (now part of
the Administration for Community
Living) has submitted the following
proposed collection of information to
OMB for review and clearance.
Section 104 (42 U.S.C. 15004) of the
Developmental Disabilities Assistance
and Bill of Rights Act of 2000 (DD Act
of 2000) directs the Secretary of Health
and Human Services to develop and
implement a system of program
accountability to monitor the grantees
funded under the DD Act of 2000. The
program accountability system shall
include the National Network of
University Centers for Excellence in
Developmental Disabilities Education,
Research, and Service (UCEDDs)
authorized under Part D of the DD Act
of 2000. In addition to the
accountability system, Section 154 (e)
(42 U.S.C. 15064) of the DD Act of 2000
includes requirements for a UCEDD
Annual Report.
The proposed data collection tools
may be found on the ACL/AIDD Web
VerDate Sep<11>2014
18:51 Sep 28, 2016
Jkt 238001
site at: https://www.acl.gov/Programs/
AIDD/Program_Resource_Search/
Results_UCEDD.aspx. AIDD estimates
the burden of this collection of
information as 1,412 average burden
hours per responses, for 67 UCEDDs,—
Total burden is 94,604 hours per year.
Dated: September 22, 2016.
Edwin L. Walker,
Acting Administrator.
[FR Doc. 2016–23488 Filed 9–28–16; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–D–1143]
Use of Nucleic Acid Tests To Reduce
the Risk of Transmission of West Nile
Virus From Living Donors of Human
Cells, Tissues, and Cellular and
Tissue-Based Products; Guidance for
Industry; Correction
AGENCY:
Food and Drug Administration,
HHS.
Notice of availability;
correction.
ACTION:
The Food and Drug
Administration (FDA or Agency) is
correcting a notice that appeared in the
Federal Register of Tuesday, September
13, 2016 (81 FR 62910). The document
announced the availability of a guidance
for industry entitled ‘‘Use of Nucleic
Acid Tests to Reduce the Risk of
Transmission of West Nile Virus from
Living Donors of Human Cells, Tissues,
and Cellular and Tissue-Based Products
(HCT/Ps). The document was published
with incorrect information of a
comment period due date. This
document corrects that error.
FOR FURTHER INFORMATION CONTACT:
Jonathan McKnight, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301,
Silver Spring, MD 20993–0002, 240–
402–7911.
SUPPLEMENTARY INFORMATION: In the
Federal Register of September 13, 2016,
in FR Doc. 2016–21969, on page 62910,
the following correction is made:
On page 62910, in the first column
under the DATES: caption, the sentence
is corrected to read, ‘‘Submit either
electronic or written comments on
Agency guidances at any time.’’
SUMMARY:
Dated: September 23, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–23514 Filed 9–28–16; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
66967
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1619]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Current Good
Manufacturing Practice in
Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary
Supplements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (the PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
invites comments on the information
collection provisions of FDA’s
regulations regarding current good
manufacturing practice (CGMP) for
dietary supplements.
DATES: Submit either electronic or
written comments on the collection of
information by November 28, 2016.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
E:\FR\FM\29SEN1.SGM
29SEN1
66968
Federal Register / Vol. 81, No. 189 / Thursday, September 29, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–N–1619 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; Current
Good Manufacturing Practice in
Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary
Supplements.’’ Received comments will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
VerDate Sep<11>2014
18:51 Sep 28, 2016
Jkt 238001
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A63, 11601 Landsdown
St., North Bethesda, MD 20852,
PRAStaff@fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Current Good Manufacturing Practice
in Manufacturing, Packaging, Labeling,
or Holding Operations for Dietary
Supplements—21 CFR Part 111; OMB
Control Number 0910–0606—Extension
On October 25, 1994, the Dietary
Supplement Health and Education Act
(DSHEA) (Pub. L. 103–417) was signed
into law. DSHEA, among other things,
amended the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) by adding
section 402(g) of the FD&C Act (21
U.S.C. 342(g)). Section 402(g)(2) of the
FD&C Act provides, in part, that the
Secretary of Health and Human Services
may, by regulation, prescribe good
manufacturing practices for dietary
supplements. Section 402(g) of the
FD&C Act also stipulates that such
regulations will be modeled after CGMP
regulations for food and may not impose
standards for which there are no
current, and generally available,
analytical methodology. Section
402(g)(1) of the FD&C Act states that a
dietary supplement is adulterated if ‘‘it
has been prepared, packed, or held
under conditions that do not meet
current good manufacturing practice
regulations.’’ Under section 701(a) of the
FD&C Act (21 U.S.C. 371), FDA may
issue regulations necessary for the
efficient enforcement of the FD&C Act.
In the Federal Register of June 25, 2007
(72 FR 34752), (the June 25, 2007, final
rule), FDA published a final rule that
established, in part 111 (21 CFR part
111), the minimum CGMP necessary for
activities related to manufacturing,
packaging, labeling, or holding dietary
supplements to ensure the quality of the
dietary supplement.
Records are an indispensable
component of CGMP. The records
required by FDA’s regulations in part
111 provide the foundation for the
planning, control, and improvement
processes that constitute a quality
control system. Implementation of these
processes in a manufacturing operation
serves as the backbone to CGMP. The
records show what is to be
manufactured; what was, in fact,
manufactured; and whether the controls
that the manufacturer put in place to
ensure the identity, purity, strength, and
composition and limits on contaminants
and to prevent adulteration were
effective. Further, records will show
whether and what deviations from
control processes occurred, facilitate
evaluation and corrective action
concerning these deviations (including,
where necessary, whether associated
batches of product should be recalled
from the marketplace), and enable a
manufacturer to assure that the
corrective action was effective. In
E:\FR\FM\29SEN1.SGM
29SEN1
Federal Register / Vol. 81, No. 189 / Thursday, September 29, 2016 / Notices
addition, by establishing recordkeeping
requirements, FDA can ensure that
industry follows CGMP during
manufacturing, packaging, labeling, or
holding operations. The regulations in
part 111 establish the minimum
manufacturing practices necessary to
ensure that dietary supplements are
manufactured, packaged, labeled, or
held in a manner that will ensure the
quality of the dietary supplements
during manufacturing, packaging,
labeling or holding operations.
The recordkeeping requirements of
the regulations include establishing
written procedures and maintaining
records pertaining to: (1) Personnel; (2)
sanitation; (3) calibration of instruments
and controls; (4) calibration, inspection,
or checks of automated, mechanical, or
electronic equipment; (5) maintaining,
cleaning, and sanitizing equipment and
utensils and other contact surfaces; (6)
water used that may become a
component of the dietary supplement;
(7) production and process controls; (8)
quality control; (9) components,
packaging, labels and product received
for packaging and labeling; (10) master
manufacturing and batch production;
(11) laboratory operations; (12)
manufacturing operations; (13)
packaging and labeling operations; (14)
holding and distributing operations; (15)
returned dietary supplements; and (16)
product complaints.
Description of Respondents:
Manufacturers, dietary supplement
manufacturers, packagers and
repackagers, labelers and re-labelers,
holders, distributors, warehousers,
exporters, importers, large businesses,
and small businesses engaged in the
dietary supplement industry.
The recordkeeping requirements of
the regulations in part 111 are set forth
in each subpart. In table 1 of this
document, we list the annual burdens
associated with recordkeeping, as
described in the June 25, 2007, final
rule. For some provisions listed in table
1, we did not estimate the number of
records per recordkeeper because
recordkeeping occasions consist of
frequent brief entries of dates,
temperatures, monitoring results, or
documentation that specific actions
were taken. Information might be
recorded a few times a day, week, or
month. When the records burden
involves frequent brief entries, we
entered 1 as the default for the number
of records per recordkeeper. For
example, many of the records listed
under § 111.35 in table 1, such as
§ 111.35(b)(2) (documentation, in
individual equipment logs, of the date
of the use, maintenance, cleaning, and
sanitizing of equipment), involve many
short sporadic entries over the course of
the year, varying across equipment and
plants in the industry. We did not
attempt to estimate the actual number of
recordkeeping occasions for these
provisions, but instead entered an
66969
estimate of the average number of hours
per year. We entered the default value
of 1 as the number of records per
recordkeeper for these and similar
provisions. For § 111.35, the entry for
number of records is 1 as a default
representing a large number of brief
recordkeeping occasions.
In many rows of table 1 of this
document, we list a burden under a
single provision that covers the written
procedures or records described in
several provisions. For example, the
burden of the batch production records
listed in table 1 under § 111.260
includes the burden for records listed
under § 111.255 because the batch
production records must include those
records. The number of records for
batch production records (and other
records kept on a batch basis in table 1
of this document) equals the annual
number of batches. The estimated
burden for records kept by batch
includes both records kept for every
batch and records kept for some but not
all batches. We use the annual number
of batches as the number of records that
will not necessarily be kept for every
batch, such as test results or material
review and disposition records, because
such records are part of records, if they
are necessary, that will be kept for every
batch.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
mstockstill on DSK3G9T082PROD with NOTICES
21 CFR Section
111.14, Records of personnel practices, including documentation of training.
111.23, Records of physical plant sanitation practices,
including pest control and water quality.
111.35, Records of equipment and utensils calibration
and sanitation practices.
111.95, Records of production and process control systems.
111.140, Records that quality control personnel must
make and keep.
111.180, Records associated with components, packaging, labels, and product received for packaging and
labeling as a dietary supplement.
111.210, Requirements for what the master manufacturing record must include.
111.260, Requirements for what the batch record must
include.
111.325, Records that quality control personnel must
make and keep for laboratory operations.
111.375, Records of the written procedures established
for manufacturing operations.
111.430, Records of the written procedures for packaging and labeling operations.
111.475, Records of product distribution and procedures
for holding and distributing operations.
111.535, Records for returned dietary supplements ........
VerDate Sep<11>2014
18:51 Sep 28, 2016
Jkt 238001
PO 00000
Frm 00051
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
Total hours
15,000
4
60,000
1 .......................
60,000
15,000
1
15,000
0.2 (12 minutes)
3,000
400
1
400
12.5 ..................
5,000
250
1
250
45 .....................
11,250
240
1,163
279,120
1 .......................
279,120
240
1,163
279,120
1 .......................
279,120
240
1
240
2.5 ....................
600
145
1,408
204,160
1 .......................
204,160
120
1
120
15 .....................
1,800
260
1
260
2 .......................
520
50
1
50
12.6 ..................
630
15,000
1
15,000
0.4 (24 minutes)
6,000
110
4
440
13.5 ..................
5,940
Fmt 4703
Sfmt 4703
E:\FR\FM\29SEN1.SGM
29SEN1
66970
Federal Register / Vol. 81, No. 189 / Thursday, September 29, 2016 / Notices
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1—Continued
Number of
recordkeepers
21 CFR Section
Number of
records per
recordkeeper
Average
burden per
recordkeeping
Total annual
records
Total hours
111.570, Records regarding product complaints ..............
240
600
144,000
0.5 (30 minutes)
72,000
Total ...........................................................................
........................
........................
........................
...........................
929,140
mstockstill on DSK3G9T082PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The average burden per recordkeeping
estimates in Table 1 of this document
are based on those in the June 25, 2007,
final rule, which were based on our
institutional experience with other
CGMP requirements and on data
provided by Research Triangle Institute
in the ‘‘Survey of Manufacturing
Practices in the Dietary Supplement
Industry’’ cited in that rule.
The estimates in table 1 of the number
of firms affected by each provision of
part 111 are based on the percentage of
manufacturers, packagers, labelers,
holders, distributors, and warehousers
that reported in the survey that they
have not established written SOPs or do
not maintain records that were later
required by the June 25, 2007, final rule.
Because we do not have survey results
for general warehouses, we entered the
approximate number of facilities in that
category for those provisions covering
general facilities. For the dietary
supplement industry, the survey
estimated that 1,460 firms would be
covered by the final rule, including
manufacturers, packagers, labelers,
holders, distributors, and warehousers.
The time estimates include the burden
involved in documenting that certain
requirements are performed and in
recordkeeping. We used an estimated
annual batch production of 1,408
batches per year to estimate the burden
of requirements that are related to the
number of batches produced annually,
such as § 111.260, ‘‘What must the batch
production record include?’’ The
estimate of 1,408 batches per year is
near the midpoint of the number of
annual batches reported by survey
firms.
The length of time that CGMP records
must be maintained is set forth in
§ 111.605. Table 1 of this document
reflects the estimated burdens for
written procedures, record maintenance,
periodically reviewing records to
determine if they may be discarded, and
for any associated documentation for
that activity for records that are required
under part 111. We have not included
a separate estimate of burden for those
sections that require maintaining
records in accordance with § 111.605,
but have included those burdens under
VerDate Sep<11>2014
18:51 Sep 28, 2016
Jkt 238001
specific provisions for keeping records.
For example, § 111.255(a) requires that
the batch production records be
prepared every time a batch is
manufactured, and § 111.255(d) requires
that batch production records be kept in
accordance with § 111.605. The
estimated burdens for both § 111.255(a)
and (d) are included under § 111.260,
what the batch record must include.
Dated: September 23, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–23521 Filed 9–28–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–3326]
Biosimilar User Fee Act; Public
Meeting; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Dated: September 23, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–23523 Filed 9–28–16; 8:45 am]
The Food and Drug
Administration is correcting a notice
entitled ‘‘Biosimilar User Fee Act;
Public Meeting’’ that appeared in the
Federal Register of September 19, 2016
(81 FR 64171). The document
announced a public meeting to discuss
proposed recommendations for the
reauthorization of the Biosimilar User
Fee Act (BsUFA) for fiscal years (FYs)
2018 through 2022. The document was
published with the incorrect date of the
closure of the docket and incorrect
transcript information. This document
corrects those errors.
FOR FURTHER INFORMATION CONTACT: Lisa
Granger, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32,
Rm. 3330, Silver Spring, MD 20993–
0002, 301–796–9115, lisa.granger@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of Monday, September
19, 2016, in FR Doc. 2016–22442, the
following corrections are made:
1. On page 64172, in the first column,
in the third sentence of the DATES
SUMMARY:
section, ‘‘October 19, 2016’’ is corrected
to read ‘‘October 28, 2016.’’
2. On page 64175, in the third
column, the section ‘‘Transcripts: As
soon as a transcript is available, FDA
will post it at https://www.fda.gov/
ForIndustry/UserFees/BiosimilarUser
FeeActBsUFA/ucm461774.htm.’’ is
corrected to read ‘‘Transcripts: Please be
advised that as soon as a transcript is
available, it will be accessible at https://
www.regulations.gov and https://
www.fda.gov/ForIndustry/UserFees/
BiosimilarUserFeeActBsUFA/
ucm461774.htm. It may be viewed at the
Division of Dockets Management, Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD. A
transcript will also be available in either
hardcopy or on CD–ROM, after
submission of a Freedom of Information
request. The Freedom of Information
office address is available on the
Agency’s Web site at https://
www.fda.gov.’’
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources And Services
Administration
National Vaccine Injury Compensation
Program; List of Petitions Received
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
HRSA is publishing this
notice of petitions received under the
National Vaccine Injury Compensation
Program (the Program), as required by
Section 2112(b)(2) of the Public Health
Service (PHS) Act, as amended. While
the Secretary of HHS (the Secretary) is
named as the respondent in all
proceedings brought by the filing of
petitions for compensation under the
Program, the United States Court of
Federal Claims is charged by statute
SUMMARY:
E:\FR\FM\29SEN1.SGM
29SEN1
Agencies
[Federal Register Volume 81, Number 189 (Thursday, September 29, 2016)]
[Notices]
[Pages 66967-66970]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23521]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1619]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Current Good Manufacturing Practice in Manufacturing,
Packaging, Labeling, or Holding Operations for Dietary Supplements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice invites comments on the information collection
provisions of FDA's regulations regarding current good manufacturing
practice (CGMP) for dietary supplements.
DATES: Submit either electronic or written comments on the collection
of information by November 28, 2016.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you
[[Page 66968]]
do not wish to be made available to the public, submit the comment as a
written/paper submission and in the manner detailed (see ``Written/
Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2013-N-1619 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Current Good Manufacturing
Practice in Manufacturing, Packaging, Labeling, or Holding Operations
for Dietary Supplements.'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A63, 11601
Landsdown St., North Bethesda, MD 20852, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Current Good Manufacturing Practice in Manufacturing, Packaging,
Labeling, or Holding Operations for Dietary Supplements--21 CFR Part
111; OMB Control Number 0910-0606--Extension
On October 25, 1994, the Dietary Supplement Health and Education
Act (DSHEA) (Pub. L. 103-417) was signed into law. DSHEA, among other
things, amended the Federal Food, Drug, and Cosmetic Act (the FD&C Act)
by adding section 402(g) of the FD&C Act (21 U.S.C. 342(g)). Section
402(g)(2) of the FD&C Act provides, in part, that the Secretary of
Health and Human Services may, by regulation, prescribe good
manufacturing practices for dietary supplements. Section 402(g) of the
FD&C Act also stipulates that such regulations will be modeled after
CGMP regulations for food and may not impose standards for which there
are no current, and generally available, analytical methodology.
Section 402(g)(1) of the FD&C Act states that a dietary supplement is
adulterated if ``it has been prepared, packed, or held under conditions
that do not meet current good manufacturing practice regulations.''
Under section 701(a) of the FD&C Act (21 U.S.C. 371), FDA may issue
regulations necessary for the efficient enforcement of the FD&C Act. In
the Federal Register of June 25, 2007 (72 FR 34752), (the June 25,
2007, final rule), FDA published a final rule that established, in part
111 (21 CFR part 111), the minimum CGMP necessary for activities
related to manufacturing, packaging, labeling, or holding dietary
supplements to ensure the quality of the dietary supplement.
Records are an indispensable component of CGMP. The records
required by FDA's regulations in part 111 provide the foundation for
the planning, control, and improvement processes that constitute a
quality control system. Implementation of these processes in a
manufacturing operation serves as the backbone to CGMP. The records
show what is to be manufactured; what was, in fact, manufactured; and
whether the controls that the manufacturer put in place to ensure the
identity, purity, strength, and composition and limits on contaminants
and to prevent adulteration were effective. Further, records will show
whether and what deviations from control processes occurred, facilitate
evaluation and corrective action concerning these deviations
(including, where necessary, whether associated batches of product
should be recalled from the marketplace), and enable a manufacturer to
assure that the corrective action was effective. In
[[Page 66969]]
addition, by establishing recordkeeping requirements, FDA can ensure
that industry follows CGMP during manufacturing, packaging, labeling,
or holding operations. The regulations in part 111 establish the
minimum manufacturing practices necessary to ensure that dietary
supplements are manufactured, packaged, labeled, or held in a manner
that will ensure the quality of the dietary supplements during
manufacturing, packaging, labeling or holding operations.
The recordkeeping requirements of the regulations include
establishing written procedures and maintaining records pertaining to:
(1) Personnel; (2) sanitation; (3) calibration of instruments and
controls; (4) calibration, inspection, or checks of automated,
mechanical, or electronic equipment; (5) maintaining, cleaning, and
sanitizing equipment and utensils and other contact surfaces; (6) water
used that may become a component of the dietary supplement; (7)
production and process controls; (8) quality control; (9) components,
packaging, labels and product received for packaging and labeling; (10)
master manufacturing and batch production; (11) laboratory operations;
(12) manufacturing operations; (13) packaging and labeling operations;
(14) holding and distributing operations; (15) returned dietary
supplements; and (16) product complaints.
Description of Respondents: Manufacturers, dietary supplement
manufacturers, packagers and repackagers, labelers and re-labelers,
holders, distributors, warehousers, exporters, importers, large
businesses, and small businesses engaged in the dietary supplement
industry.
The recordkeeping requirements of the regulations in part 111 are
set forth in each subpart. In table 1 of this document, we list the
annual burdens associated with recordkeeping, as described in the June
25, 2007, final rule. For some provisions listed in table 1, we did not
estimate the number of records per recordkeeper because recordkeeping
occasions consist of frequent brief entries of dates, temperatures,
monitoring results, or documentation that specific actions were taken.
Information might be recorded a few times a day, week, or month. When
the records burden involves frequent brief entries, we entered 1 as the
default for the number of records per recordkeeper. For example, many
of the records listed under Sec. 111.35 in table 1, such as Sec.
111.35(b)(2) (documentation, in individual equipment logs, of the date
of the use, maintenance, cleaning, and sanitizing of equipment),
involve many short sporadic entries over the course of the year,
varying across equipment and plants in the industry. We did not attempt
to estimate the actual number of recordkeeping occasions for these
provisions, but instead entered an estimate of the average number of
hours per year. We entered the default value of 1 as the number of
records per recordkeeper for these and similar provisions. For Sec.
111.35, the entry for number of records is 1 as a default representing
a large number of brief recordkeeping occasions.
In many rows of table 1 of this document, we list a burden under a
single provision that covers the written procedures or records
described in several provisions. For example, the burden of the batch
production records listed in table 1 under Sec. 111.260 includes the
burden for records listed under Sec. 111.255 because the batch
production records must include those records. The number of records
for batch production records (and other records kept on a batch basis
in table 1 of this document) equals the annual number of batches. The
estimated burden for records kept by batch includes both records kept
for every batch and records kept for some but not all batches. We use
the annual number of batches as the number of records that will not
necessarily be kept for every batch, such as test results or material
review and disposition records, because such records are part of
records, if they are necessary, that will be kept for every batch.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Recordkeeping Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of records per Total annual Average burden per recordkeeping Total hours
recordkeepers recordkeeper records
--------------------------------------------------------------------------------------------------------------------------------------------------------
111.14, Records of personnel practices, 15,000 4 60,000 1...................................... 60,000
including documentation of training.
111.23, Records of physical plant sanitation 15,000 1 15,000 0.2 (12 minutes)....................... 3,000
practices, including pest control and water
quality.
111.35, Records of equipment and utensils 400 1 400 12.5................................... 5,000
calibration and sanitation practices.
111.95, Records of production and process 250 1 250 45..................................... 11,250
control systems.
111.140, Records that quality control personnel 240 1,163 279,120 1...................................... 279,120
must make and keep.
111.180, Records associated with components, 240 1,163 279,120 1...................................... 279,120
packaging, labels, and product received for
packaging and labeling as a dietary supplement.
111.210, Requirements for what the master 240 1 240 2.5.................................... 600
manufacturing record must include.
111.260, Requirements for what the batch record 145 1,408 204,160 1...................................... 204,160
must include.
111.325, Records that quality control personnel 120 1 120 15..................................... 1,800
must make and keep for laboratory operations.
111.375, Records of the written procedures 260 1 260 2...................................... 520
established for manufacturing operations.
111.430, Records of the written procedures for 50 1 50 12.6................................... 630
packaging and labeling operations.
111.475, Records of product distribution and 15,000 1 15,000 0.4 (24 minutes)....................... 6,000
procedures for holding and distributing
operations.
111.535, Records for returned dietary 110 4 440 13.5................................... 5,940
supplements.
[[Page 66970]]
111.570, Records regarding product complaints.. 240 600 144,000 0.5 (30 minutes)....................... 72,000
--------------------------------------------------------------------------------------------------------
Total...................................... .............. .............. .............. ....................................... 929,140
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
The average burden per recordkeeping estimates in Table 1 of this
document are based on those in the June 25, 2007, final rule, which
were based on our institutional experience with other CGMP requirements
and on data provided by Research Triangle Institute in the ``Survey of
Manufacturing Practices in the Dietary Supplement Industry'' cited in
that rule.
The estimates in table 1 of the number of firms affected by each
provision of part 111 are based on the percentage of manufacturers,
packagers, labelers, holders, distributors, and warehousers that
reported in the survey that they have not established written SOPs or
do not maintain records that were later required by the June 25, 2007,
final rule. Because we do not have survey results for general
warehouses, we entered the approximate number of facilities in that
category for those provisions covering general facilities. For the
dietary supplement industry, the survey estimated that 1,460 firms
would be covered by the final rule, including manufacturers, packagers,
labelers, holders, distributors, and warehousers. The time estimates
include the burden involved in documenting that certain requirements
are performed and in recordkeeping. We used an estimated annual batch
production of 1,408 batches per year to estimate the burden of
requirements that are related to the number of batches produced
annually, such as Sec. 111.260, ``What must the batch production
record include?'' The estimate of 1,408 batches per year is near the
midpoint of the number of annual batches reported by survey firms.
The length of time that CGMP records must be maintained is set
forth in Sec. 111.605. Table 1 of this document reflects the estimated
burdens for written procedures, record maintenance, periodically
reviewing records to determine if they may be discarded, and for any
associated documentation for that activity for records that are
required under part 111. We have not included a separate estimate of
burden for those sections that require maintaining records in
accordance with Sec. 111.605, but have included those burdens under
specific provisions for keeping records. For example, Sec. 111.255(a)
requires that the batch production records be prepared every time a
batch is manufactured, and Sec. 111.255(d) requires that batch
production records be kept in accordance with Sec. 111.605. The
estimated burdens for both Sec. 111.255(a) and (d) are included under
Sec. 111.260, what the batch record must include.
Dated: September 23, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-23521 Filed 9-28-16; 8:45 am]
BILLING CODE 4164-01-P